We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Response Trial of Pergolide for Cocaine Dependence - 1

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000248
First Posted: September 21, 1999
Last Update Posted: September 13, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by:
Medical University of South Carolina
  Purpose
The purpose of this study is to evaluate the efficacy and safety of pergolide for treatment of cocaine dependence.

Condition Intervention Phase
Cocaine-Related Disorders Drug: Pergolide Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Dose Response Trial of Pergolide for Cocaine Dependence

Resource links provided by NLM:


Further study details as provided by Medical University of South Carolina:

Primary Outcome Measures:
  • Side effects
  • Drug use
  • Retention
  • Cocaine withdrawal
  • Compliance
  • Effectiveness of medication for global improvements

Estimated Enrollment: 0
Study Start Date: February 1996
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000248


Locations
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425 742
Sponsors and Collaborators
Medical University of South Carolina
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Robert Malcolm, M.D. Medical University of South Carolina
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00000248     History of Changes
Other Study ID Numbers: NIDA-08355-1
R01DA008355 ( U.S. NIH Grant/Contract )
R01-08355-1
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: September 13, 2012
Last Verified: May 1997

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Pergolide
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Dopamine Agonists